Resumen

RODRIGUEZ-FERRERAS, A  y  ZAPICO-GARCIA, I. Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report. Anales Sis San Navarra [online]. 2019, vol.42, n.1, pp.75-78.  Epub 21-Oct-2019. ISSN 1137-6627.  https://dx.doi.org/10.23938/assn.0392.

Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT).

We describe the case of a patient with an excellent performance status who was allowed to undergo alogenic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results.

Palabras clave : Blinatumomab; Philadelphia chromosome negative; Stem cell transplantation; Minimal residual disease; Refractory acute lymphoblastic leukemia.

        · resumen en Español     · texto en Español     · Español ( pdf )